Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
CONCLUSION: The maximum tolerated dose was not determined because slow accrual resulted in early study termination.
PMID: 32048771 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Patel SP, Pakkala S, Pennell NA, Reckamp KL, Lanzalone S, Polli A, Tarazi J, Robert-Vizcarrondo F Tags: Oncologist Source Type: research
More News: Cancer | Cancer & Oncology | Lessons | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Study | Toxicology | Translocation